Point72 Asset Management L.P. Makes New $526,000 Investment in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Point72 Asset Management L.P. bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,596,344 shares of the company's stock, valued at approximately $526,000. Point72 Asset Management L.P. owned about 85.37% of Tonix Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Jane Street Group LLC increased its holdings in shares of Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock valued at $548,000 after acquiring an additional 1,635,119 shares during the last quarter. Northern Trust Corp bought a new stake in Tonix Pharmaceuticals during the fourth quarter worth approximately $162,000. Geode Capital Management LLC boosted its position in Tonix Pharmaceuticals by 1,600.1% during the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company's stock worth $650,000 after purchasing an additional 1,855,907 shares during the period. Commonwealth Equity Services LLC acquired a new position in Tonix Pharmaceuticals during the fourth quarter valued at approximately $40,000. Finally, PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals during the 4th quarter worth $72,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Seth Lederman bought 4,000 shares of the business's stock in a transaction that occurred on Thursday, May 15th. The stock was acquired at an average cost of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the purchase, the chief executive officer now owns 4,005 shares of the company's stock, valued at $86,307.75. This trade represents a 80,000.00% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.03% of the company's stock.

Tonix Pharmaceuticals Stock Performance

Tonix Pharmaceuticals stock traded down $1.95 during mid-day trading on Wednesday, reaching $35.04. The company had a trading volume of 595,875 shares, compared to its average volume of 873,671. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The firm has a market cap of $256.66 million, a price-to-earnings ratio of -0.01 and a beta of 1.63. The company has a 50 day moving average of $20.78 and a 200-day moving average of $21.66. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $6.76 and a 52 week high of $574.08.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.39. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.43 million during the quarter, compared to analysts' expectations of $2.55 million. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Noble Financial reiterated an "outperform" rating and issued a $70.00 target price on shares of Tonix Pharmaceuticals in a report on Thursday, March 20th. Wall Street Zen raised Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd.

Tonix Pharmaceuticals Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.